NCT04997551 is a Phase 3 clinical trial of Colchcine in COVID-19 Infection, sponsored by Biogipuzkoa Health Research Institute.

Who is sponsoring NCT04997551?

NCT04997551 is sponsored by Biogipuzkoa Health Research Institute.

What drugs are being tested in NCT04997551?

Interventions in NCT04997551: Colchcine.

What condition does NCT04997551 study?

NCT04997551 studies COVID-19 Infection.

Is NCT04997551 still recruiting?

NCT04997551 is currently status unknown. Last updated 9 August 2021.

Last reviewed 2021-08-09 · How we verify

NCT04997551

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19

Status unknown Phase 3 Last updated 9 August 2021

What this trial tests

Phase 3 trial testing Colchcine in COVID-19 Infection in 752 participants. Status unknown.

Timeline

8 September 2020

Primary endpoint
1 September 2021

1 January 2022

Quick facts

Lead sponsor	Biogipuzkoa Health Research Institute
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	752
Start date	8 September 2020
Primary completion	1 September 2021
Estimated completion	1 January 2022
Sites	1 location across Spain

Drugs / interventions tested

Colchcine — full drug profile →

Conditions studied

COVID-19 Infection — all drugs for COVID-19 Infection →

Sponsor

Biogipuzkoa Health Research Institute

Who can join

Adults 18 to 99, any sex, with COVID-19 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

EC CORONACOLCHI is a multicenter, double-blind and randomized clinical trial with two branches. Patients who meet all the inclusion criteria and none of the exclusion criteria will be randomized 1: 1 to be included in one of the following groups: * Experimental group: colchicine for 2 weeks orally at the doses described, added to the standard treatment of COVID-19. * Control group: placebo for 2 weeks orally added to standard COVID-19 treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COVID-19 Infection

Currently open trials in the same condition.

NCT07013474 — A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised · Phase 3 · recruiting
NCT06965751 — A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 · Phase 1 · active not recruiting
NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT05672355 — A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia · Phase 2 · recruiting
NCT05774093 — Evaluation of COVID-19 Immune Barrier and Reinfection Risk · recruiting

Other Biogipuzkoa Health Research Institute trials

Trials by the same sponsor.

NCT07270393 — Study of the Influence of the Mediterranean Diet on the Quality of Life of Patients With Endometriosis. · NA · not yet recruiting
NCT07414212 — Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosi · Phase 1, PHASE2 · recruiting
NCT06660446 — Exercise During Chemotherapy Treatment As Adjuvant Program in Patients with Lymphoma: EDONOLA Study. · NA · recruiting
NCT05489185 — Clinical Trial to Assess the Efficacy of Tranexamic Acid in Reducing Blood Loss in Hip Fracture Patients. · Phase 4 · unknown
NCT05622760 — Impact of the Different Information Channels in Reducing Anxiety in Participants of Cervical Cancer Screening · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04997551 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biogipuzkoa Health Research Institute
Last refreshed: 9 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04997551.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing